JP7502863B2 - 光線角化症を治療および／または予防する方法 - Google Patents
光線角化症を治療および／または予防する方法 Download PDFInfo
- Publication number
- JP7502863B2 JP7502863B2 JP2019549396A JP2019549396A JP7502863B2 JP 7502863 B2 JP7502863 B2 JP 7502863B2 JP 2019549396 A JP2019549396 A JP 2019549396A JP 2019549396 A JP2019549396 A JP 2019549396A JP 7502863 B2 JP7502863 B2 JP 7502863B2
- Authority
- JP
- Japan
- Prior art keywords
- administered
- days
- subject
- day
- affected area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 179
- 208000009621 actinic keratosis Diseases 0.000 title claims description 134
- 238000011282 treatment Methods 0.000 claims description 172
- 230000000694 effects Effects 0.000 claims description 37
- 206010040914 Skin reaction Diseases 0.000 claims description 35
- 210000004761 scalp Anatomy 0.000 claims description 35
- 230000035483 skin reaction Effects 0.000 claims description 35
- 231100000430 skin reaction Toxicity 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 32
- 230000002411 adverse Effects 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- 210000000245 forearm Anatomy 0.000 claims description 21
- 210000001508 eye Anatomy 0.000 claims description 14
- 206010003051 Application site pain Diseases 0.000 claims description 12
- 230000008961 swelling Effects 0.000 claims description 11
- 208000003367 Hypopigmentation Diseases 0.000 claims description 10
- 208000025865 Ulcer Diseases 0.000 claims description 10
- 230000003628 erosive effect Effects 0.000 claims description 10
- 210000001061 forehead Anatomy 0.000 claims description 10
- 208000000069 hyperpigmentation Diseases 0.000 claims description 10
- 230000003810 hyperpigmentation Effects 0.000 claims description 10
- 230000003425 hypopigmentation Effects 0.000 claims description 10
- 230000036269 ulceration Effects 0.000 claims description 10
- 206010019233 Headaches Diseases 0.000 claims description 8
- 231100000869 headache Toxicity 0.000 claims description 8
- 206010015967 Eye swelling Diseases 0.000 claims description 7
- 206010049041 Application site infection Diseases 0.000 claims description 6
- 206010003046 Application site irritation Diseases 0.000 claims description 6
- 206010003053 Application site pruritus Diseases 0.000 claims description 6
- 206010053424 Application site swelling Diseases 0.000 claims description 6
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 6
- 201000007100 Pharyngitis Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 210000005069 ears Anatomy 0.000 claims description 6
- 210000000744 eyelid Anatomy 0.000 claims description 6
- 201000009240 nasopharyngitis Diseases 0.000 claims description 6
- 230000003902 lesion Effects 0.000 description 74
- VDJHFHXMUKFKET-UHFFFAOYSA-N Ingenol mebutate Natural products CC1CC2C(C)(C)C2C2C=C(CO)C(O)C3(O)C(OC(=O)C(C)=CC)C(C)=CC31C2=O VDJHFHXMUKFKET-UHFFFAOYSA-N 0.000 description 40
- VDJHFHXMUKFKET-WDUFCVPESA-N ingenol mebutate Chemical compound C[C@@H]1C[C@H]2C(C)(C)[C@H]2[C@@H]2C=C(CO)[C@@H](O)[C@]3(O)[C@@H](OC(=O)C(\C)=C/C)C(C)=C[C@]31C2=O VDJHFHXMUKFKET-WDUFCVPESA-N 0.000 description 40
- 229960002993 ingenol mebutate Drugs 0.000 description 23
- 229940107670 picato Drugs 0.000 description 17
- 206010015150 Erythema Diseases 0.000 description 14
- 230000000699 topical effect Effects 0.000 description 14
- 206010040844 Skin exfoliation Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 238000012216 screening Methods 0.000 description 9
- 239000002131 composite material Substances 0.000 description 8
- 231100000321 erythema Toxicity 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000037390 scarring Effects 0.000 description 7
- 206010004146 Basal cell carcinoma Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- 206010042674 Swelling Diseases 0.000 description 6
- 229940000406 drug candidate Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000002547 new drug Substances 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 206010059516 Skin toxicity Diseases 0.000 description 4
- 238000000315 cryotherapy Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 231100000438 skin toxicity Toxicity 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 206010003055 Application site reaction Diseases 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 3
- 229960002751 imiquimod Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 201000002481 Myositis Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 206010041101 Small intestinal obstruction Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229960002749 aminolevulinic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002681 cryosurgery Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001329 hyperkeratotic effect Effects 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000013105 post hoc analysis Methods 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- -1 salt compound Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 206010056951 Actinic cheilitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 206010053459 Secretion discharge Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 208000011873 mild conjunctivitis Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001079 no serious adverse effect Toxicity 0.000 description 1
- 231100001099 no skin toxicity Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 239000000697 oral hormonal contraceptive Substances 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000014731 pulmonary artery disease Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022180723A JP2023015269A (ja) | 2017-03-10 | 2022-11-11 | 光線角化症を治療および／または予防する方法 |
| JP2024207319A JP2025029010A (ja) | 2017-03-10 | 2024-11-28 | 光線角化症を治療および／または予防する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762469889P | 2017-03-10 | 2017-03-10 | |
| US62/469,889 | 2017-03-10 | ||
| PCT/US2018/021929 WO2018165647A1 (en) | 2017-03-10 | 2018-03-12 | Methods of treating and/or preventing actinic keratosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022180723A Division JP2023015269A (ja) | 2017-03-10 | 2022-11-11 | 光線角化症を治療および／または予防する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510042A JP2020510042A (ja) | 2020-04-02 |
| JP2020510042A5 JP2020510042A5 (enExample) | 2021-04-08 |
| JP7502863B2 true JP7502863B2 (ja) | 2024-06-19 |
Family
ID=63446658
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549396A Active JP7502863B2 (ja) | 2017-03-10 | 2018-03-12 | 光線角化症を治療および／または予防する方法 |
| JP2022180723A Pending JP2023015269A (ja) | 2017-03-10 | 2022-11-11 | 光線角化症を治療および／または予防する方法 |
| JP2024207319A Pending JP2025029010A (ja) | 2017-03-10 | 2024-11-28 | 光線角化症を治療および／または予防する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022180723A Pending JP2023015269A (ja) | 2017-03-10 | 2022-11-11 | 光線角化症を治療および／または予防する方法 |
| JP2024207319A Pending JP2025029010A (ja) | 2017-03-10 | 2024-11-28 | 光線角化症を治療および／または予防する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10617693B2 (enExample) |
| EP (2) | EP4659740A2 (enExample) |
| JP (3) | JP7502863B2 (enExample) |
| KR (2) | KR20190141661A (enExample) |
| CN (1) | CN110891575A (enExample) |
| AU (2) | AU2018231144B2 (enExample) |
| BR (1) | BR112019018687A2 (enExample) |
| CA (1) | CA3055938A1 (enExample) |
| IL (1) | IL269182B2 (enExample) |
| MX (2) | MX387658B (enExample) |
| TW (1) | TWI841523B (enExample) |
| WO (1) | WO2018165647A1 (enExample) |
| ZA (1) | ZA202100106B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7968574B2 (en) * | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| TWI841523B (zh) * | 2017-03-10 | 2024-05-11 | 美商Ａｔｎｘ特殊目的實體公司 | 治療及／或預防光化性角化症之方法 |
| SG11202001868RA (en) | 2017-09-07 | 2020-03-30 | Athenex Hk Innovative Ltd | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide |
| US11752156B2 (en) * | 2018-03-07 | 2023-09-12 | Athenex HK Innovative Limited | Compositions and methods for treating hyperproliferative skin disorders |
| WO2019188918A1 (ja) * | 2018-03-28 | 2019-10-03 | テルモ株式会社 | 医療デバイスおよび処置用法 |
| US20220305021A1 (en) * | 2019-06-05 | 2022-09-29 | Athenex, Inc. | Methods of treating and/or preventing psoriasis |
| EP4263833A1 (en) * | 2021-01-21 | 2023-10-25 | Sirnaomics, Inc. | Compositions and methods for treatment of skin cancers |
| WO2025077886A1 (zh) * | 2023-10-13 | 2025-04-17 | 恩康药业科技（广州）有限公司 | 治疗和/或预防日光性角化病的化合物及方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103274961B (zh) | 2004-12-28 | 2016-05-18 | 阿西纳斯公司 | 治疗细胞增殖紊乱的化合物和方法 |
| US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| CA2656564C (en) | 2006-06-29 | 2015-06-16 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
| US7538252B2 (en) | 2006-09-05 | 2009-05-26 | Bipar Sciences, Inc. | Drug design for tubulin inhibitors, compositions, and methods of treatment thereof |
| US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
| TWI457336B (zh) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
| US7939529B2 (en) | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| CA2686267C (en) | 2007-05-17 | 2015-10-06 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| EP2143421A1 (en) | 2008-07-07 | 2010-01-13 | Almirall Hermal GmbH | Topical composition for the treatment of actinic keratosis |
| DK2378876T3 (en) * | 2008-12-19 | 2019-03-11 | Medicis Pharmaceutical Corp | IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS |
| US8741857B1 (en) | 2012-01-30 | 2014-06-03 | Lawrence Moy | Treatments for actinic keratoses |
| NZ606177A (en) | 2012-01-30 | 2014-03-28 | Dolorgiet Gmbh & Co Kg | Compositions for the treatment of actinic keratosis |
| MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
| TWI841523B (zh) * | 2017-03-10 | 2024-05-11 | 美商Ａｔｎｘ特殊目的實體公司 | 治療及／或預防光化性角化症之方法 |
-
2018
- 2018-03-12 TW TW107108242A patent/TWI841523B/zh active
- 2018-03-12 AU AU2018231144A patent/AU2018231144B2/en active Active
- 2018-03-12 CN CN201880029861.9A patent/CN110891575A/zh active Pending
- 2018-03-12 WO PCT/US2018/021929 patent/WO2018165647A1/en not_active Ceased
- 2018-03-12 KR KR1020197029678A patent/KR20190141661A/ko not_active Ceased
- 2018-03-12 IL IL269182A patent/IL269182B2/en unknown
- 2018-03-12 JP JP2019549396A patent/JP7502863B2/ja active Active
- 2018-03-12 MX MX2019010707A patent/MX387658B/es unknown
- 2018-03-12 EP EP25210508.5A patent/EP4659740A2/en active Pending
- 2018-03-12 CA CA3055938A patent/CA3055938A1/en active Pending
- 2018-03-12 EP EP18764980.1A patent/EP3592355B1/en active Active
- 2018-03-12 KR KR1020247017149A patent/KR20240090837A/ko active Pending
- 2018-03-12 BR BR112019018687-5A patent/BR112019018687A2/pt not_active Application Discontinuation
- 2018-03-12 US US15/918,100 patent/US10617693B2/en active Active
-
2019
- 2019-09-09 MX MX2021013354A patent/MX2021013354A/es unknown
-
2020
- 2020-02-28 US US16/804,092 patent/US11497750B2/en active Active
-
2021
- 2021-01-07 ZA ZA2021/00106A patent/ZA202100106B/en unknown
-
2022
- 2022-10-11 US US17/963,502 patent/US20230172942A1/en active Pending
- 2022-11-11 JP JP2022180723A patent/JP2023015269A/ja active Pending
-
2024
- 2024-03-20 AU AU2024201828A patent/AU2024201828A1/en active Pending
- 2024-11-28 JP JP2024207319A patent/JP2025029010A/ja active Pending
Non-Patent Citations (3)
| Title |
|---|
| 「新医薬品の臨床評価に関する一般指針について」（薬新薬第４３号）各都道府県衛生主管部長宛厚生省薬務，１９９２年０６月２９日 |
| ＮＣＴ０２３３７２０５，ＣｌｉｎｉｃａｌＴｒｉａｌｓ．ｇｏｖ，２０１６年，ｐ．１－４ |
| ＮＣＴ０２８３８６２８，ＣｌｉｎｉｃａｌＴｒｉａｌｓ．ｇｏｖ，２０１６年，ｐ．１－５ |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4659740A2 (en) | 2025-12-10 |
| JP2020510042A (ja) | 2020-04-02 |
| EP3592355B1 (en) | 2025-12-10 |
| TW201842913A (zh) | 2018-12-16 |
| US20180256589A1 (en) | 2018-09-13 |
| AU2018231144A1 (en) | 2019-10-03 |
| KR20190141661A (ko) | 2019-12-24 |
| ZA202100106B (en) | 2022-08-31 |
| EP3592355A1 (en) | 2020-01-15 |
| KR20240090837A (ko) | 2024-06-21 |
| IL269182B1 (en) | 2023-07-01 |
| WO2018165647A1 (en) | 2018-09-13 |
| US11497750B2 (en) | 2022-11-15 |
| JP2025029010A (ja) | 2025-03-05 |
| AU2024201828A1 (en) | 2024-05-02 |
| IL269182B2 (en) | 2023-11-01 |
| BR112019018687A2 (pt) | 2020-04-07 |
| US20230172942A1 (en) | 2023-06-08 |
| MX2021013354A (es) | 2021-11-18 |
| US20200197405A1 (en) | 2020-06-25 |
| CN110891575A (zh) | 2020-03-17 |
| JP2023015269A (ja) | 2023-01-31 |
| TWI841523B (zh) | 2024-05-11 |
| CA3055938A1 (en) | 2018-09-13 |
| RU2019131757A (ru) | 2021-04-12 |
| IL269182A (en) | 2019-11-28 |
| AU2018231144B2 (en) | 2023-12-21 |
| MX387658B (es) | 2025-03-18 |
| US10617693B2 (en) | 2020-04-14 |
| RU2019131757A3 (enExample) | 2021-05-31 |
| MX2019010707A (es) | 2020-01-15 |
| EP3592355A4 (en) | 2021-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7502863B2 (ja) | 光線角化症を治療および／または予防する方法 | |
| Sharma et al. | Rosacea management: A comprehensive review | |
| Dahl et al. | Once-daily topical metronidazole cream formulations in the treatment of the papules and pustules of rosacea | |
| US11938099B2 (en) | Use of tapinarof for the treatment of atopic dermatitis | |
| CN105792829A (zh) | 使用伊维菌素治疗丘疹脓疱性红斑痤疮 | |
| WO2008150929A1 (en) | Topical compositions comprising a macromolecule and methods of using same | |
| EP3154517B1 (en) | Stabilized oxymetazoline formulations and their uses | |
| US20160089362A1 (en) | Method for Topically Treating Actinic Keratosis on the Trunk (except chest) or Extremities with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate) | |
| RU2805929C2 (ru) | Способы лечения и/или предотвращения актинического кератоза | |
| Mokadem et al. | Intralesional methotrexate versus curettage and application of 100% trichloroacetic acid in planter warts | |
| BR122025000862A2 (pt) | Usos do composto kx-01 no tratamento e/ou prevenção da ceratose actínica | |
| Neelima et al. | Comprehensive Evaluation of Intradermal Versus Oral Tranexamic Acid in The Treatment of Melasma. | |
| Borelli et al. | Topical and Systemic Therapy of Rosacea | |
| JP2024506953A (ja) | Ｐｌａｑｕｅ乾癬、アトピー性皮膚炎、放射線性皮膚炎の治療におけるタピナロフの改善効果 | |
| TW202519195A (zh) | 苯酚衍生物的溶液型藥物組合物及其製劑和用途 | |
| TW202112379A (zh) | 治療及／或預防乾癬之方法 | |
| Pump | Pr Taro-Imiquimod Pr Taro-Imiquimod Pump | |
| Dermotoi | Therapeutics 45 | |
| Xu et al. | Medical Dermatology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210224 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210224 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210401 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211116 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211122 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220511 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220711 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20221111 |
|
| C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20221124 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20221124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221209 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230421 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230421 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240607 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7502863 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |